These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19344572)

  • 1. Optical imaging of cellular immunotherapy against prostate cancer.
    Tavri S; Jha P; Meier R; Henning TD; Müller T; Hostetter D; Knopp C; Johansson M; Reinhart V; Boddington S; Sista A; Wels WS; Daldrup-Link HE
    Mol Imaging; 2009; 8(1):15-26. PubMed ID: 19344572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging.
    Meier R; Golovko D; Tavri S; Henning TD; Knopp C; Piontek G; Rudelius M; Heinrich P; Wels WS; Daldrup-Link H
    Magn Reson Med; 2011 Mar; 65(3):756-63. PubMed ID: 20928869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Near-infrared emitting fluorescent nanocrystals-labeled natural killer cells as a platform technology for the optical imaging of immunotherapeutic cells-based cancer therapy.
    Lim YT; Cho MY; Noh YW; Chung JW; Chung BH
    Nanotechnology; 2009 Nov; 20(47):475102. PubMed ID: 19875875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
    Hall SJ; Sanford MA; Atkinson G; Chen SH
    Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
    Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
    Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
    Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
    Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
    Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells.
    Nakashima Y; Deie M; Yanada S; Sharman P; Ochi M
    Int J Oncol; 2005 Oct; 27(4):965-71. PubMed ID: 16142312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.
    Meier R; Piert M; Piontek G; Rudelius M; Oostendorp RA; Senekowitsch-Schmidtke R; Henning TD; Wels WS; Uherek C; Rummeny EJ; Daldrup-Link HE
    Nucl Med Biol; 2008 Jul; 35(5):579-88. PubMed ID: 18589302
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.